JP2006522144A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006522144A5 JP2006522144A5 JP2006509595A JP2006509595A JP2006522144A5 JP 2006522144 A5 JP2006522144 A5 JP 2006522144A5 JP 2006509595 A JP2006509595 A JP 2006509595A JP 2006509595 A JP2006509595 A JP 2006509595A JP 2006522144 A5 JP2006522144 A5 JP 2006522144A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- use according
- group
- compound
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 17
- 208000024891 symptom Diseases 0.000 claims 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 208000008967 Enuresis Diseases 0.000 claims 5
- 206010020853 Hypertonic bladder Diseases 0.000 claims 5
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 206010029446 nocturia Diseases 0.000 claims 5
- 208000020629 overactive bladder Diseases 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- -1 troches Substances 0.000 claims 5
- 206010036018 Pollakiuria Diseases 0.000 claims 4
- 208000026723 Urinary tract disease Diseases 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000022934 urinary frequency Diseases 0.000 claims 4
- 208000014001 urinary system disease Diseases 0.000 claims 4
- 230000036318 urination frequency Effects 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 3
- 230000001629 suppression Effects 0.000 claims 3
- GZXONPGTMHLBKQ-UTONKHPSSA-N 2,3-dihydroindol-1-yl-[(5r)-4,5,6,7-tetrahydro-3h-benzimidazol-5-yl]methanone;hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2N1C(=O)[C@H]1CC(NC=N2)=C2CC1 GZXONPGTMHLBKQ-UTONKHPSSA-N 0.000 claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 2
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 claims 2
- 229960002430 atomoxetine Drugs 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229950001588 ramosetron Drugs 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 claims 1
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 claims 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 claims 1
- DBXKJORICFHAQA-UHFFFAOYSA-N 2-[(2-methylimidazol-1-yl)methyl]benzo[f]thiochromen-1-one;hydrochloride Chemical compound Cl.CC1=NC=CN1CC1=CSC2=CC=C(C=CC=C3)C3=C2C1=O DBXKJORICFHAQA-UHFFFAOYSA-N 0.000 claims 1
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- MJCKISCWHDATBN-UHFFFAOYSA-N 4-amino-5-chloro-n-[(1-ethyl-4,5-dihydroimidazol-2-yl)methyl]-2-methoxybenzamide Chemical compound CCN1CCN=C1CNC(=O)C1=CC(Cl)=C(N)C=C1OC MJCKISCWHDATBN-UHFFFAOYSA-N 0.000 claims 1
- FEROPKNOYKURCJ-UHFFFAOYSA-N 4-amino-N-(1-azabicyclo[2.2.2]octan-3-yl)-5-chloro-2-methoxybenzamide Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)NC1C(CC2)CCN2C1 FEROPKNOYKURCJ-UHFFFAOYSA-N 0.000 claims 1
- DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 206010027566 Micturition urgency Diseases 0.000 claims 1
- WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 claims 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 206010036968 Prostatic pain Diseases 0.000 claims 1
- JJZXGTBGAPUCHC-PBWFPOADSA-N [(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-ethyl-2-oxobenzimidazole-1-carboxylate Chemical compound C1[C@@H](N2C)CC[C@@H]2CC1OC(=O)N1C2=CC=CC=C2N(CC)C1=O JJZXGTBGAPUCHC-PBWFPOADSA-N 0.000 claims 1
- 239000000013 adrenergic uptake inhibitor Substances 0.000 claims 1
- FLZQKRKHLSUHOR-UHFFFAOYSA-N alosetron Chemical compound CC1=NC=N[C]1CN1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FLZQKRKHLSUHOR-UHFFFAOYSA-N 0.000 claims 1
- 229960003550 alosetron Drugs 0.000 claims 1
- 230000008485 antagonism Effects 0.000 claims 1
- 229950005951 azasetron Drugs 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- MNJNPLVXBISNSX-WDNDVIMCSA-N bemesetron Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C1=CC(Cl)=CC(Cl)=C1 MNJNPLVXBISNSX-WDNDVIMCSA-N 0.000 claims 1
- 229950007840 bemesetron Drugs 0.000 claims 1
- 239000007894 caplet Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- SPKBYQZELVEOLL-QDMKHBRRSA-N chembl2111147 Chemical compound N([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C1=CC(Cl)=CC2=C1OC(C)(C)C2 SPKBYQZELVEOLL-QDMKHBRRSA-N 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 125000002993 cycloalkylene group Chemical group 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 229960003914 desipramine Drugs 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229960002866 duloxetine Drugs 0.000 claims 1
- 239000007897 gelcap Substances 0.000 claims 1
- 229960003727 granisetron Drugs 0.000 claims 1
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- MHNNVDILNTUWNS-XYYAHUGASA-N indisetron Chemical group C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CN(C[C@@H](C3)N4C)C)=NNC2=C1 MHNNVDILNTUWNS-XYYAHUGASA-N 0.000 claims 1
- 229950007467 indisetron Drugs 0.000 claims 1
- RWXRJSRJIITQAK-ZSBIGDGJSA-N itasetron Chemical compound C12=CC=CC=C2NC(=O)N1C(=O)N[C@H](C1)C[C@H]2CC[C@@H]1N2C RWXRJSRJIITQAK-ZSBIGDGJSA-N 0.000 claims 1
- 229950007654 itasetron Drugs 0.000 claims 1
- 229950002371 lintopride Drugs 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 claims 1
- 229960004090 maprotiline Drugs 0.000 claims 1
- 230000027939 micturition Effects 0.000 claims 1
- 229960000600 milnacipran Drugs 0.000 claims 1
- AFOFVIBWSLOHFR-GOOCMWNKSA-N n-[(1r,5s)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl]-2-oxo-3-propan-2-ylbenzimidazole-1-carboxamide Chemical compound C1[C@@H](N2C)CC[C@@H]2CC1NC(=O)N1C2=CC=CC=C2N(C(C)C)C1=O AFOFVIBWSLOHFR-GOOCMWNKSA-N 0.000 claims 1
- KOYCUQMOCJHRJC-MLOZCBHJSA-N n-[(1s,5r)-3,9-dimethyl-3,9-diazabicyclo[3.3.1]nonan-7-yl]-1h-indazole-3-carboxamide;hydron;dichloride Chemical compound Cl.Cl.C1=CC=C2C(C(=O)NC3C[C@H]4CN(C[C@@H](C3)N4C)C)=NNC2=C1 KOYCUQMOCJHRJC-MLOZCBHJSA-N 0.000 claims 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 1
- 229940126569 noradrenaline reuptake inhibitor Drugs 0.000 claims 1
- 229960001158 nortriptyline Drugs 0.000 claims 1
- 229960005343 ondansetron Drugs 0.000 claims 1
- FDXQKWSTUZCCTM-UHFFFAOYSA-N oxaprotiline Chemical compound C12=CC=CC=C2C2(CC(O)CNC)C3=CC=CC=C3C1CC2 FDXQKWSTUZCCTM-UHFFFAOYSA-N 0.000 claims 1
- 229960002131 palonosetron Drugs 0.000 claims 1
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- NTHPAPBPFQJABD-LLVKDONJSA-N ramosetron Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)[C@H]1CC(NC=N2)=C2CC1 NTHPAPBPFQJABD-LLVKDONJSA-N 0.000 claims 1
- 229960003770 reboxetine Drugs 0.000 claims 1
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 claims 1
- 229950003039 renzapride Drugs 0.000 claims 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 239000006188 syrup Substances 0.000 claims 1
- 235000020357 syrup Nutrition 0.000 claims 1
- 229950008418 talipexole Drugs 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 229960003688 tropisetron Drugs 0.000 claims 1
- UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 claims 1
- 239000002966 varnish Substances 0.000 claims 1
- 229960004688 venlafaxine Drugs 0.000 claims 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical group C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 1
- 229960001255 viloxazine Drugs 0.000 claims 1
- 229950004681 zacopride Drugs 0.000 claims 1
- 229950001074 zatosetron Drugs 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46102203P | 2003-04-04 | 2003-04-04 | |
| US49650203P | 2003-08-20 | 2003-08-20 | |
| US53634104P | 2004-01-13 | 2004-01-13 | |
| PCT/US2004/010088 WO2004089288A2 (en) | 2003-04-04 | 2004-04-02 | Method of treating lower urinary tract disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006522144A JP2006522144A (ja) | 2006-09-28 |
| JP2006522144A5 true JP2006522144A5 (https=) | 2007-04-05 |
Family
ID=33162987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006509595A Pending JP2006522144A (ja) | 2003-04-04 | 2004-04-02 | 下部尿路障害の治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US6846823B2 (https=) |
| EP (1) | EP1539181B1 (https=) |
| JP (1) | JP2006522144A (https=) |
| AT (1) | ATE365554T1 (https=) |
| AU (1) | AU2004227945B2 (https=) |
| CA (1) | CA2519379A1 (https=) |
| DE (1) | DE602004007225T2 (https=) |
| ES (1) | ES2290741T3 (https=) |
| WO (1) | WO2004089288A2 (https=) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7085845B2 (en) * | 2001-05-09 | 2006-08-01 | Gene Fein | Method, apparatus and computer program product for identifying a playing media file and tracking associated user preferences |
| CN100355419C (zh) * | 2002-06-07 | 2007-12-19 | 安斯泰来制药有限公司 | 治疗膀胱过度活动的药物 |
| US20040180958A1 (en) * | 2002-12-13 | 2004-09-16 | Taylor Charles Price | Method of treatment |
| AU2003301184A1 (en) * | 2002-12-20 | 2004-07-22 | Dynogen Pharmaceuticals Inc | METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING Alpha2Delta SUBUNIT CALCIUM CHANNEL MODULATORS |
| AU2004224322A1 (en) * | 2003-03-21 | 2004-10-07 | Dynogen Pharmaceuticals, Inc. | Methods of treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators |
| JP2006522144A (ja) * | 2003-04-04 | 2006-09-28 | ダイノゲン ファーマシューティカルズ，インコーポレイテッド | 下部尿路障害の治療方法 |
| JP5548329B2 (ja) * | 2003-08-04 | 2014-07-16 | 杏林製薬株式会社 | 経皮吸収型製剤 |
| EP1727527A1 (en) * | 2004-03-19 | 2006-12-06 | Solvay Pharmaceuticals GmbH | Use of a 5-ht3 receptor antagonist for the manufacture of a medicament for the treatment of non-digestive tract derived abdominal disorders associated with pain |
| US7820690B2 (en) | 2004-03-19 | 2010-10-26 | Solvay Pharmaceuticals Gmbh | Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist |
| CA2580170A1 (en) * | 2004-10-18 | 2006-04-27 | Boehringer Ingelheim International Gmbh | Use of a beta-3 agonist for treating complaints of the prostate and the lower urogenital tract |
| US7985736B2 (en) * | 2004-12-14 | 2011-07-26 | The John Hopkins University | High throughput screen utilizing newly discovered intramolecular neuronal calcium channel interactions to discover new analgesics |
| CN101132777A (zh) | 2004-12-20 | 2008-02-27 | 科利吉姆制药公司 | 用于睡眠障碍的药物组合物 |
| KR20140002082A (ko) * | 2005-01-14 | 2014-01-07 | 유리젠, 인코포레이티드 | 하부 요로 장애 치료용 키트 및 개선된 조성물 |
| EP1855680A2 (en) * | 2005-02-25 | 2007-11-21 | Solvay Pharmaceuticals, Inc. | Method of treatment of diarrhea-predominant ibs in a female subject receiving contraceptive therapy |
| WO2006105117A2 (en) * | 2005-03-28 | 2006-10-05 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
| US20070093520A1 (en) * | 2005-04-15 | 2007-04-26 | Caras Steven D | Method of treatment of diarrhea-predominant irritable bowel syndrome in a subject |
| US20070010543A1 (en) * | 2005-07-01 | 2007-01-11 | Dynogen Pharmaceuticals, Inc. | Compositions and methods for treating gastrointestinal hypomotility and associated disorders |
| EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| FR2895259B1 (fr) * | 2005-12-22 | 2008-02-22 | Urosphere Sas | Methodes de traitement des incontinences urinaires |
| US20070172508A1 (en) * | 2006-01-26 | 2007-07-26 | Paul Zupkas | Transluminal drug delivery methods and devices |
| US20070172507A1 (en) * | 2006-01-26 | 2007-07-26 | Paul Zupkas | Transluminal drug delivery methods and devices |
| US20070244143A1 (en) * | 2006-03-08 | 2007-10-18 | Braincells, Inc | Modulation of neurogenesis by nootropic agents |
| US20100216734A1 (en) * | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| JP2009536667A (ja) * | 2006-05-09 | 2009-10-15 | ブレインセルス，インコーポレイティド | ５ｈｔ受容体介在性の神経新生 |
| EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100009983A1 (en) * | 2006-05-09 | 2010-01-14 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| AU2007292848A1 (en) * | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| AU2007299920A1 (en) * | 2006-09-19 | 2008-03-27 | Braincells, Inc. | PPAR Mediated Modulation of Neurogenesis |
| US7975699B2 (en) * | 2007-10-30 | 2011-07-12 | The Invention Science Fund I, Llc | Condoms configured to facilitate release of nitric oxide |
| US8642093B2 (en) | 2007-10-30 | 2014-02-04 | The Invention Science Fund I, Llc | Methods and systems for use of photolyzable nitric oxide donors |
| EP1997807A1 (en) * | 2007-05-28 | 2008-12-03 | Laboratorios del Dr. Esteve S.A. | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments |
| CA2673545A1 (en) * | 2006-12-22 | 2008-07-03 | Recordati Ireland Limited | Combination therapy of lower urinary tract disorders with .alpha.2.delta. ligands and nsaids |
| AU2008204800A1 (en) * | 2007-01-11 | 2008-07-17 | Braincells, Inc. | Modulation of neurogenesis with use of modafinil |
| US20090274722A1 (en) * | 2007-01-29 | 2009-11-05 | Ligums John E | Therapeutic Composition for the Treatment of BPH and ED |
| EP2136863A2 (en) * | 2007-03-19 | 2009-12-30 | Insuline Medical Ltd. | Device for drug delivery and associated connections thereto |
| US8622991B2 (en) | 2007-03-19 | 2014-01-07 | Insuline Medical Ltd. | Method and device for drug delivery |
| WO2009081262A1 (en) | 2007-12-18 | 2009-07-02 | Insuline Medical Ltd. | Drug delivery device with sensor for closed-loop operation |
| US9220837B2 (en) | 2007-03-19 | 2015-12-29 | Insuline Medical Ltd. | Method and device for drug delivery |
| CN104069567A (zh) * | 2007-03-19 | 2014-10-01 | 茵苏莱恩医药有限公司 | 药物输送设备 |
| BRPI0812000A2 (pt) * | 2007-05-30 | 2014-11-18 | Microdose Therapeutx Inc | Métodos e composições para administração de oxibutinina |
| US9119777B2 (en) | 2008-05-30 | 2015-09-01 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| US8415390B2 (en) * | 2008-05-30 | 2013-04-09 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| US20110171195A1 (en) * | 2007-06-15 | 2011-07-14 | Duke University | Methods and compositions for treating urinary tract infections using agents that mimic or elevate cyclic amp |
| US8877508B2 (en) | 2007-10-30 | 2014-11-04 | The Invention Science Fund I, Llc | Devices and systems that deliver nitric oxide |
| US10080823B2 (en) * | 2007-10-30 | 2018-09-25 | Gearbox Llc | Substrates for nitric oxide releasing devices |
| US20110182970A1 (en) * | 2007-10-30 | 2011-07-28 | Hyde Roderick A | Nitric oxide sensors and systems |
| CA2704298C (en) | 2007-11-02 | 2015-07-21 | Astellas Pharma Inc. | Pharmaceutical composition for treating overactive bladder |
| EP2288345B1 (en) | 2008-04-18 | 2015-06-10 | University College Dublin National University Of Ireland, Dublin | Psycho-pharmaceuticals |
| AU2009312474B2 (en) | 2008-11-07 | 2014-12-04 | Insuline Medical Ltd. | Device and method for drug delivery |
| EP2364138A2 (en) * | 2008-12-08 | 2011-09-14 | Teva Pharmaceutical Industries Ltd. | Palonosetron formulation |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US9180263B2 (en) * | 2009-07-01 | 2015-11-10 | Microdose Therapeutx, Inc. | Laboratory animal pulmonary dosing device |
| US20110000481A1 (en) * | 2009-07-01 | 2011-01-06 | Anand Gumaste | Nebulizer for infants and respiratory compromised patients |
| CN105381524A (zh) | 2010-01-05 | 2016-03-09 | 微剂量治疗技术公司 | 吸入设备和方法 |
| US10238821B2 (en) | 2016-10-11 | 2019-03-26 | Microdose Therapeutx, Inc. | Inhaler and methods of use thereof |
| WO2020030777A1 (en) * | 2018-08-10 | 2020-02-13 | Grünenthal GmbH | Composition for treating urinary frequency and/or urinary urgency |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3046489A (en) | 1958-11-28 | 1962-07-24 | Elcor Inc | Wide band direct coupled amplifier |
| ES274725A1 (es) | 1961-02-04 | 1962-06-16 | Orlandi Giorgio | Aparato de distanciamiento de filamentos, cordones y cintas de pasta alimenticia para hacer seguir a camaras y hornos de fermentaciën y cochura |
| JPS60146891A (ja) * | 1984-01-05 | 1985-08-02 | Mitsubishi Chem Ind Ltd | 〔２，３−ｄ〕チエノピリミジン誘導体およびその塩 |
| DE3422155A1 (de) | 1984-06-14 | 1985-12-19 | Alfred Teves Gmbh, 6000 Frankfurt | Hydraulische servofahrzeugbremse |
| EP0299053A1 (en) | 1987-01-30 | 1989-01-18 | American Home Products Corporation | Des-epidermal growth factor plasminogen activators |
| DE3885357T2 (de) * | 1987-06-29 | 1994-03-24 | Duphar Int Res | Anellierte Indolderivate. |
| US5225407A (en) * | 1990-02-22 | 1993-07-06 | Glaxo Group Limited | 5-HT3 receptor antagonists for the treatment of autism |
| CA2044854A1 (en) * | 1990-07-19 | 1992-01-20 | Hong-I Chen | Method for preventing or treating urinary incontinence |
| CA2061665C (en) * | 1991-02-25 | 2002-04-16 | Mark Mortensen Foreman | Treatment of lower urinary tract disorders |
| JPH06508836A (ja) * | 1991-06-26 | 1994-10-06 | セプラコア，インコーポレーテッド | 光学的に純粋なｒ（＋）オンダンセトロンを使用する嘔吐、吐き気および他の障害の治療のための方法および組成物 |
| US5281624A (en) * | 1991-09-27 | 1994-01-25 | Eli Lilly And Company | N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof |
| JP2699794B2 (ja) * | 1992-03-12 | 1998-01-19 | 三菱化学株式会社 | チエノ〔３，２−ｂ〕ピリジン誘導体 |
| JPH0616557A (ja) * | 1992-12-21 | 1994-01-25 | Mitsubishi Kasei Corp | 脳機能障害改善剤 |
| TW344661B (en) * | 1993-11-24 | 1998-11-11 | Lilly Co Eli | Pharmaceutical composition for treatment of incontinence |
| DK0855397T3 (da) * | 1995-07-28 | 2001-06-25 | Dainippon Pharmaceutical Co | (R)-5-brom-N-(ethyl-4-methylhexahydro-1H-1,4-diazepin-6-yl)-2-methoxy-6-methylamino-3-pyridincarboxamid, fremgangsmåde til dets fremstilling og medicinsk præparat indeholdende denne forbindelse |
| AU702594B2 (en) * | 1995-10-13 | 1999-02-25 | Duphar International Research B.V. | Process for the preparation of enantiomerically pure imidazolyl compounds |
| PT975327E (pt) | 1997-04-18 | 2003-11-28 | Janssen Pharmaceutica Nv | Uso de antagonistas de 5ht3 para estimular a lavagem intestinal |
| JPH10298078A (ja) | 1997-05-06 | 1998-11-10 | Mitsubishi Chem Corp | 抗不安薬 |
| DE19813661A1 (de) * | 1997-08-01 | 1999-02-04 | Solvay Pharm Gmbh | Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron |
| DE19734444A1 (de) * | 1997-08-08 | 1999-02-11 | Basf Ag | 3-Substituierte 3,4,5,7-Tetrahydro-pyrrolo(3',4':4,5) thieno (2,3-d) pyrimidin-Derivate, ihre Herstellung und Verwendung |
| FR2781671A1 (fr) | 1998-07-28 | 2000-02-04 | Synthelabo | Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique |
| EP1123923A4 (en) | 1998-10-23 | 2002-11-27 | Ajinomoto Kk | DIHYDROPYRIDINE DERIVATIVES AND DRUG BLOCK CONTAINING THESE |
| US6272553B2 (en) * | 1998-11-20 | 2001-08-07 | Sprint Communications Company, L.P. | Multi-services communications device |
| AU3422800A (en) | 1999-02-18 | 2000-09-04 | Novartis Ag | Use of 5-ht3 receptor antagonists |
| US6342496B1 (en) * | 1999-03-01 | 2002-01-29 | Sepracor Inc. | Bupropion metabolites and methods of use |
| DE19911371A1 (de) * | 1999-03-15 | 2000-09-21 | Solvay Pharm Gmbh | Arzneimittel zur Behandlung von funktionellen Störungen und Erkrankungen der unteren Darmwege, insbesondere von damit einhergehenden abdominalen visceralen Schmerzen |
| US6589570B1 (en) * | 1999-04-12 | 2003-07-08 | University Of Madras | Pharmaceutical formulation useful for the treatment of hepatitis B, hepatitis C and other viral infections of the liver and a process for its preparation |
| DE19929197A1 (de) * | 1999-06-25 | 2000-12-28 | Novosis Pharma Ag | Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung |
| DE60022692T2 (de) * | 1999-07-01 | 2006-06-22 | Pharmacia & Upjohn Co. Llc, Kalamazoo | (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen |
| GB2355191A (en) | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
| US6846496B1 (en) * | 1999-10-15 | 2005-01-25 | Orion Corporation | Treatment of osteoporosis |
| WO2001051496A1 (en) * | 2000-01-14 | 2001-07-19 | Rhodia, Inc. | Crosslinking agents for textile finishing baths |
| PT1257277E (pt) * | 2000-02-24 | 2005-09-30 | Pharmacia & Upjohn Co Llc | Novas combinacoes de farmacos |
| JP2002026134A (ja) * | 2000-07-12 | 2002-01-25 | Seiko Epson Corp | 半導体集積回路の製造方法及びこの方法により製造した半導体集積回路 |
| GB0112494D0 (en) | 2001-05-22 | 2001-07-11 | Arachnova Therapeutics Ltd | New therapeutic use |
| US20040048874A1 (en) * | 2001-05-22 | 2004-03-11 | Bardsley Hazel Judith | New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine |
| DE60312474T2 (de) | 2002-01-18 | 2007-12-06 | Aryx Therapeutics, Fremont | 5-ht3-rezeptorantagonisten und verwendungsverfahren |
| GB0202265D0 (en) | 2002-01-31 | 2002-03-20 | Arachnova Therapeutics Ltd | New therapeutic use |
| CA2479350A1 (en) * | 2002-03-15 | 2003-09-25 | Cypress Bioscience, Inc. | Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes |
| CA2491836C (en) | 2002-07-10 | 2011-01-25 | Arachnova Therapeutics Ltd. | 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-d) pyrimidine in the treatment of functional bowel disorder |
| BR0313836A (pt) | 2002-08-29 | 2005-06-21 | Arachnova Therapeutics Ltd | Novos usos terapêuticos de 4-(2-fluorofenil)-6-metil-2-(1-piperazinil)tieno[2,3-d]pi rimidina |
| JP2006516977A (ja) * | 2003-01-13 | 2006-07-13 | ダイノゲン ファーマシューティカルズ，インコーポレイテッド | 悪心、嘔吐、レッチング、またはそれらの任意の組み合わせの治療方法 |
| MXPA05007381A (es) * | 2003-01-13 | 2006-02-10 | Dynogen Pharmaceuticals Inc | Metodo para el tratamiento de transtornos funcionales del intestino. |
| JP2006522144A (ja) * | 2003-04-04 | 2006-09-28 | ダイノゲン ファーマシューティカルズ，インコーポレイテッド | 下部尿路障害の治療方法 |
| US7356884B2 (en) * | 2003-12-18 | 2008-04-15 | 3M Innovative Properties Company | Fastener for a display page |
-
2004
- 2004-04-02 JP JP2006509595A patent/JP2006522144A/ja active Pending
- 2004-04-02 AT AT04758741T patent/ATE365554T1/de not_active IP Right Cessation
- 2004-04-02 ES ES04758741T patent/ES2290741T3/es not_active Expired - Lifetime
- 2004-04-02 US US10/817,332 patent/US6846823B2/en not_active Expired - Fee Related
- 2004-04-02 AU AU2004227945A patent/AU2004227945B2/en not_active Ceased
- 2004-04-02 EP EP04758741A patent/EP1539181B1/en not_active Expired - Lifetime
- 2004-04-02 CA CA002519379A patent/CA2519379A1/en not_active Abandoned
- 2004-04-02 DE DE602004007225T patent/DE602004007225T2/de not_active Expired - Fee Related
- 2004-04-02 WO PCT/US2004/010088 patent/WO2004089288A2/en not_active Ceased
- 2004-06-07 US US10/863,770 patent/US7115606B2/en not_active Expired - Fee Related
- 2004-06-07 US US10/863,771 patent/US20050020577A1/en not_active Abandoned
-
2005
- 2005-05-04 US US11/122,940 patent/US20050272719A1/en not_active Abandoned
- 2005-05-06 US US11/124,580 patent/US20050282799A1/en not_active Abandoned